Asia-Pacific API Intermediates Market Research Report – Segmentation by Type (Pharmaceutical Intermediates/Bulk Drug Intermediates, Veterinary Drug Intermediates); Product (Nitriles, Bromo Compound, Chiral PCBHP, Hemisulphate, and Others); Therapeutic Type (Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Oncology, and Others); Region – Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15213
Format:
Region: Asia Pacific
Chapter 1. Asia-Pacific API Intermediates Market – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Asia-Pacific API Intermediates Market – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. Asia-Pacific API Intermediates Market – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. Asia-Pacific API Intermediates Market - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Asia-Pacific API Intermediates Market - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Asia-Pacific API Intermediates Market - By Product
6.1. Nitriles
6.2. Bromo Compound
6.3. Chiral PCBHP
6.4. Hemisulphate
6.5. Others
Chapter 7. Asia-Pacific API Intermediates Market - By Type
7.1. Pharmaceutical Intermediates/Bulk Drug Intermediates
7.2. Veterinary Drug Intermediates
Chapter 8. Asia-Pacific API Intermediates Market - By Therapeutic Type
8.1. Cardiovascular Disease
8.2. Metabolic Disease
8.3. Respiratory Disease
8.4. Oncology
8.5. Others
Chapter 9. Asia-Pacific API Intermediates Market – By Region
9.1. China
9.2. Japan
9.3. India
9.4. South Korea
9.5. Rest of the Asia-Pacific
Chapter 10. Asia-Pacific API Intermediates Market – Company Profiles – (Overview, Product Portfolio, Financials, Developments)
10.1. Sanofi
10.2. Aarti Industries Limited
10.3. Aurobindo Pharma
10.4. Divi's Laboratories Limited.
10.5. HIKAL Ltd.
10.6. Sandoz International GmbH
10.7. BASF SE
10.8. Cambrex Corporation
10.9. AlzChem Group AG
10.10. Vasudha Pharma
10.11. Anyang General Chemical Co., Ltd.
Download Sample
Choose License Type
2500
3400
3900
4600
Frequently Asked Questions
Asia-Pacific API Intermediates Market is estimated to be worth USD 6.99 Billion in 2022 and is projected to reach a value of USD 12.01 Billion by 2030, growing at a CAGR of 7% during the forecast period 2023-2030
The Asia-Pacific API Intermediates Market is driven by the Growing Pharmaceutical Industry in the Asia-Pacific Region
The Segments under the Asia-Pacific API Intermediates Market by the Product are Nitriles, Bromo Compound, and Chiral PCBHP
China, Japan, South Korea, Singapore, and India are the most dominating countries in the Asia Pacific region for the Asia-Pacific API Intermediates Market
Sanofi, Aarti Industries Limited, and Aurobindo Pharma are the three major leading players in the Asia-Pacific API Intermediates Market.
